Redeye initiates coverage of Paxman, a Swedish/English medical technology company. They develop, produce, and market their scalp cooling system that reduces hair loss (alopecia) associated with chemotherapy. We see an attractive case with significant upside potential. Strong clinical data and positive drivers for reimbursement in the US are the right ingredients for an exciting growth journey.